The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

Evangelista, Laura; Zucchetta, Pietro; Moletta, Lucia; Serafini, Simone; Cassarino, G; Pegoraro, Nicola; Bergamo, Francesca; Sperti, Cosimo; Cecchin, Diego

doi:10.1007/s12149-021-01629-0

Cited by 33 publications

(23 citation statements)

References 22 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endoscopic ultrasound (EUS) is highly sensitive in detecting small tumors that are often missed by other imaging modalities, and it also provides an opportunity to collect samples (fine needle aspirates) for cytological or biomarker analysis to facilitate the most conclusive diagnosis 177 . Metabolic PET imaging, which relies on the differential uptake of 18 F-labeled fluoro-deoxy glucose (FDG) by rapidly growing tumor cells, enables whole-body imaging to detect both primary tumors and metastasis and is used alone or in combination with CT and MRI for evaluating the response to therapy in PDAC patients 178 , 179 . The principles, utility, and current status of various imaging modalities are elegantly reviewed in several recent articles 178 , 180 - 182 .…”

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

“…Metabolic PET imaging, which relies on the differential uptake of 18 F-labeled fluoro-deoxy glucose (FDG) by rapidly growing tumor cells, enables whole-body imaging to detect both primary tumors and metastasis and is used alone or in combination with CT and MRI for evaluating the response to therapy in PDAC patients 178 , 179 . The principles, utility, and current status of various imaging modalities are elegantly reviewed in several recent articles 178 , 180 - 182 . Imaging modalities like abdominal ultrasound utilize microbubbles as contrast agents, which have been functionalized by targeting molecules to facilitate molecular imaging.…”

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

See 1 more Smart Citation

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Liu¹,

Kshirsagar²,

Gautam³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and biochemical stresses that lead to increased interstitial fluid pressure, vascular compression, and hypoxia. Immunotherapy-based approaches, including therapeutic vaccines, immune checkpoint inhibition, CAR-T cell therapy, and adoptive T cell therapies, are challenged by an immunosuppressive tumor microenvironment. Together, extensive fibrosis and immunosuppression present major challenges to developing treatments for pancreatic cancer. In this context, nanoparticles have been extensively studied as delivery platforms and adjuvants for cancer and other disease therapies. Recent advances in nanotechnology have led to the development of multiple nanocarrier-based formulations that not only improve drug delivery but also enhance immunotherapy-based approaches for pancreatic cancer. This review discusses and critically analyzes the novel nanoscale strategies that have been used for drug delivery and immunomodulation to improve treatment efficacy, including newly emerging immunotherapy-based approaches. This review also presents important perspectives on future research directions that will guide the rational design of novel and robust nanoscale platforms to treat pancreatic tumors, particularly with respect to targeted therapies and immunotherapies. These insights will inform the next generation of clinical treatments to help patients manage this debilitating disease and enhance survival rates.

show abstract

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Liu¹,

Kshirsagar²,

Gautam³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…Flurodeoxyglucose positron emission tomography (PET)/ MRI is currently the latest examination technology in the field of magnetic resonance. 54 There is only one report on the application of PET/MRI in the NAT of PDAC. Panda et al 55 retrospectively studied the ability of PET/MRI and CT to assess the pathological response of PDAC to NAT and predict the OS in 44 patients.…”

Section: Positron Emission Tomography/magnetic Resonance Imagingmentioning

confidence: 99%

“…Flurodeoxyglucose positron emission tomography (PET)/MRI is currently the latest examination technology in the field of magnetic resonance 54 . There is only one report on the application of PET/MRI in the NAT of PDAC.…”

Section: Positron Emission Tomography/magnetic Resonance Imagingmentioning

confidence: 99%

Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma

Zeng

Wang

et al. 2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignant tumors of the human digestive system. Due to its insidious onset, many patients have already lost the opportunity for radical resection upon tumor diagnosis. In recent years, neoadjuvant treatment for patients with borderline resectable PDAC has been recommended by multiple guidelines to increase the resection rate of radical surgery and improve the postoperative survival. However, further developments are required to accurately assess the tumor response to neoadjuvant therapy and to select the population suitable for such treatment. Reductions in drug toxicity and the number of neoadjuvant cycles are also critical. At present, the clinical evaluation of neoadjuvant treatment is mainly based on several serological and imaging indicators; however, the unique characteristics of PDAC and the insufficient sensitivity and specificity of the markers render this system ineffective. The imaging evaluation system, magnetic resonance imaging (MRI), has its own unique imaging advantages compared with computed tomography (CT) and other imaging examinations. One key advantage is the ability to reflect the changes more rapidly in tumor tissue components, such as the degree of fibrosis, microvessel density, and tissue hypoxia. It can also perform multiparameter quantitative analysis of tumor tissue and changes, attributing to its increasingly important role in imaging evaluation, and potentially the evaluation of neoadjuvant treatment of pancreatic cancer, as several current articles have studied. At the same time, owing to the complexity of MRI and some of its limitations, its wider application is limited. Compared with CT imaging, few relevant studies have been conducted. In this review article, we will investigate and summarize the advantages, limitations, and future development of MRI in the evaluation of neoadjuvant treatment of PDAC. Evidence Level 3 Technical Efficacy Stage 2

show abstract

“…Post-chemotherapy metabolic responses based on positron emission tomography (PET/CT or PET/MRI) metabolic imaging as surrogates of pathologic response is currently used in some centers to evaluate treatment response ( 32 , 45 , 46 ). Metabolic response by PET/CT or PET/MRI may be a more sensitive measure of tumor response than traditional CT or MRI and should be evaluated in future clinical trials ( 47 ). Criteria to be considered in the evaluation of treatment response during neoadjuvant therapy in pancreatic cancer are presented in Table 2 .…”

Section: Evaluation Of Treatment Responsementioning

confidence: 99%

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives

Labori

2022

Front. Surg.

View full text Add to dashboard Cite

Neoadjuvant therapy improves overall survival compared with a surgery-first approach in patients with borderline resectable pancreatic cancer (BRPC). Evidence of higher quality is required to determine whether neoadjuvant therapy has potential benefits and improves survival for patients with resectable pancreatic cancer (RPC). Most randomized controlled trials (RCTs) have explored short-course neoadjuvant chemotherapy (SNT), but total neoadjuvant chemotherapy (TNT) is now the experimental arm of ongoing RCTs. This article reviews the current status of SNT and TNT in RPC and BRPC, and provides perspectives of future challenges and research directions in this field.

show abstract

The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

Cited by 33 publications

References 22 publications

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives

Contact Info

Product

Resources

About